CASI Pharmaceuticals (ENM) Stock Statistics & Valuation Metrics
Total Valuation
CASI Pharmaceuticals has a market cap or net worth of CHF 2.21M. The enterprise value is CHF 40.23M.
- Market Cap
- CHF 2.21M
- Enterprise Value
- CHF 40.23M
Share Statistics
CASI Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- ―
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
CASI Pharmaceuticals’s return on equity (ROE) is 1.29 and return on invested capital (ROIC) is -2115.85%.
- Return on Equity (ROE)
- 1.29
- Return on Assets (ROA)
- -1.87
- Return on Invested Capital (ROIC)
- -2115.85%
- Return on Capital Employed (ROCE)
- 1.78
- Revenue Per Employee
- 96.79K
- Profits Per Employee
- -224.57K
- Employee Count
- 214
- Asset Turnover
- 0.81
- Inventory Turnover
- 6.67
Valuation Ratios
The current PE Ratio of CASI Pharmaceuticals is -0.06. CASI Pharmaceuticals’s PEG ratio is -0.00.
- PE Ratio
- -0.06
- PS Ratio
- 0.13
- PB Ratio
- -0.05
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, CASI Pharmaceuticals had revenue of 20.71M and earned -48.06M in profits. Earnings per share was -2.59.
- Revenue
- 20.71M
- Gross Profit
- 10.06M
- Operating Income
- -42.85M
- Pretax Income
- -48.06M
- Net Income
- -48.06M
- EBITDA
- -43.77M
- Earnings Per Share (EPS)
- -2.59
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
CASI Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -1645.01%
Important Dates
CASI Pharmaceuticals upcoming earnings date is Nov 13, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 13, 2026
- Ex-Dividend Date
- ―
Financial Position
CASI Pharmaceuticals as a current ratio of 0.27, with Debt / Equity ratio of -73.72%
- Current Ratio
- 0.27
- Quick Ratio
- 0.24
- Debt to Market Cap
- 1.65
- Net Debt to EBITDA
- -0.50
- Interest Coverage Ratio
- -51.01
Taxes
In the past 12 months, CASI Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
CASI Pharmaceuticals EV to EBITDA ratio is -1.02, with an EV/FCF ratio of 0.00.
- EV to Sales
- 1.96
- EV to EBITDA
- -1.02
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
CASI Pharmaceuticals has CHF 3.77M in cash and marketable securities with CHF 40.50M in debt, giving a net cash position of -CHF 36.73M billion.
- Cash & Marketable Securities
- CHF 3.77M
- Total Debt
- CHF 40.50M
- Net Cash
- -CHF 36.73M
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- -CHF 2.84
Margins
Gross margin is 59.97%, with operating margin of -190.98%, and net profit margin of -218.55%.
- Gross Margin
- 59.97%
- Operating Margin
- -190.98%
- Pretax Margin
- -218.55%
- Net Profit Margin
- -218.55%
- EBITDA Margin
- -192.64%
- EBIT Margin
- -198.66%
